Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MDGL Madrigal Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: MDGL
Price (delayed)
$295.57
Market cap
$6.56B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$17.93
Enterprise value
$6.49B
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum
Highlights
The revenue has surged by 76% since the previous quarter
The company's gross profit has surged by 76% QoQ
The company's quick ratio fell by 41% YoY and by 7% QoQ
The equity is down by 16% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of MDGL
Market
Valuations
Earnings
Shares outstanding
22.2M
Market cap
$6.56B
Enterprise value
$6.49B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.18
Price to sales (P/S)
20.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.46
Revenue
$317.38M
Gross profit
$306.64M
Operating income
-$425.15M
Net income
-$391.59M
EBIT
-$377.46M
EBITDA
-$376.5M
Free cash flow
-$401.41M
Per share
Balance sheet
Liquidity
EPS
-$17.93
EPS diluted
-$17.93
Free cash flow per share
-$18.17
Book value per share
$32.18
Revenue per share
$14.37
TBVPS
$44.9
Total assets
$996.63M
Total liabilities
$285.99M
Debt
$119.77M
Equity
$710.64M
Working capital
$820.74M
Debt to equity
0.17
Current ratio
5.91
Quick ratio
5.44
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-118.6%
Gross margin
96.6%
Net margin
-123.4%
Operating margin
-134%
Return on assets
-37.2%
Return on equity
-50.5%
Return on invested capital
-50.3%
Return on capital employed
-45.5%
Return on sales
-118.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MDGL stock price
How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
-0.55%
1 week
6.23%
1 month
0.07%
1 year
6.7%
YTD
-4.21%
QTD
-10.77%
Financial performance
How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$317.38M
Gross profit
$306.64M
Operating income
-$425.15M
Net income
-$391.59M
Gross margin
96.6%
Net margin
-123.4%
The revenue has surged by 76% since the previous quarter
The company's gross profit has surged by 76% QoQ
The net margin has surged by 52% since the previous quarter
Madrigal Pharmaceuticals's operating margin has soared by 52% from the previous quarter
Price vs fundamentals
How does MDGL's price correlate with its fundamentals
Growth
What is Madrigal Pharmaceuticals's growth rate over time
Valuation
What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.18
P/S
20.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.46
The EPS has increased by 22% YoY and by 18% from the previous quarter
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 22.1 but 15% more than its last 4 quarters average of 8.0
The equity is down by 16% year-on-year and by 6% since the previous quarter
The P/S is 84% lower than the last 4 quarters average of 132.3
The revenue has surged by 76% since the previous quarter
Efficiency
How efficient is Madrigal Pharmaceuticals business performance
The ROE has soared by 61% YoY and by 12% from the previous quarter
Madrigal Pharmaceuticals's ROIC has soared by 59% YoY and by 25% from the previous quarter
MDGL's return on assets has surged by 53% year-on-year and by 14% since the previous quarter
The ROS has soared by 53% from the previous quarter
Dividends
What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MDGL.
Financial health
How did Madrigal Pharmaceuticals financials performed over time
The company's quick ratio fell by 41% YoY and by 7% QoQ
The current ratio has declined by 37% year-on-year and by 3.1% since the previous quarter
The debt is 83% smaller than the equity
Madrigal Pharmaceuticals's debt to equity has increased by 21% YoY and by 6% QoQ
The equity is down by 16% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.